Four-year outcomes of the DRCR Retina Network Protocol W study showed that preventive aflibercept vs. sham treatment in eyes with moderate to severe NPDR leads to anatomic improvement but no gain in visual acuity.
The results, published in JAMA, confirmed the findings of the previous primary analysis at 2 years.
“This study indicates that monitoring patients regularly for vision-threatening diabetes complications and treating eyes only as needed is the best approach,” Raj K. Maturi, MD, protocol chair for the 4-year study, said in a press release issued by the National (Read more...)